Abstracts tagged "inflammatory arthritis and viruses"

Abstract Number: 2808 • 2013 ACR/ARHP Annual Meeting
Favorable Outcome Of Hepatitis E Virus Infection In Patients With Inflammatory Arthritides Treated With Immunosupressants
Hélène Bauer¹, Cécile Luxembourger², Sophie Fournier³, Alain G. Cantagrel⁴, Jean Marie Peron³, Anne Marie Roque Afonso⁵, Pascal Claudepierre⁶, S. Fabre⁷, Christophe Hudry⁸, Guillaume Lefevre⁹, Antoine Martin¹⁰, Laurent Messer¹¹, Béatrice Pallot Prades¹², Christian Roux¹³, Christelle Sordet¹⁴, Claire Veissier¹⁵, Daniel Wendling¹⁶, Jacques-Eric Gottenberg¹⁷ and Jean Sibilia¹⁸, ¹rhumatologie, CHU de Hautepierre, Strasbourg, France, ²rhumatologie, CHU de Toulouse, Toulouse, France, ³Hépato-gastro-entérologie, CHU de Toulouse, Toulouse, France, ⁴Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁵INSERM U785, CNR hépatites A et E, virologie hôpital Paul Brousse, Villejuif, France, ⁶Rheumatology, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, ⁷Unité clinique d'immuno-rhumatologie, CHU MONTPELLIER, Montpellier, France, ⁸Rheumatology, Hopital Cochin, Paris, France, ⁹Lille University Hospital, Internal Medicine Department, Lille, France, ¹⁰Rhumatologie, Centre Hospitalier De St Brieuc, St Brieuc, France, ¹¹Rhumatologie, Hopitaux Civils de Colmar, Colmar, France, ¹²Rhumatologie, CHU St Etienne, St Etienne, France, ¹³Rheuamtology, CHU L' Archet University Nice, Nice, France, ¹⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁵rhumatologie, CHU de Bordeaux, Bordeaux, France, ¹⁶Rheumatology, University Hospital, Besancon, France, ¹⁷Strasbourg University Hospital, Strasbourg, France, ¹⁸Rheumatology, CHU Hautepierre, Strasbourg, France
Background/Purpose: In inflammatory rheumatic diseases, the prevalence, clinical presentation and outcome of hepatitis E, an ubiquitous viral infection, remain unknown. We therefore addressed these issues…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].